Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depression in Alzheimer's disease.

Sergio E Starkstein1, Romina Mizrahi

  • 1University of Western Australia, Education Building T-7, School of Psychiatry & Clinical Neurosciences, & Fremantle Hospital, Western Australia, Australia. ses@cyllene.uwa.edu.au

Expert Review of Neurotherapeutics
|June 21, 2006
PubMed
Summary

Depression is common in Alzheimer's disease, often underdiagnosed and undertreated. Recent trials show sertraline and moclobemide effectively treat depression in dementia patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Group Differences of Multiregion Glutamate Concentration in Clinical High Risk and Schizophrenia.

The European journal of neuroscience·2026
Same author

Gamma auditory steady-state response and remission in antipsychotic-naïve patients at clinical high risk for psychosis: a longitudinal study.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2026
Same author

Stress and synaptic density in psychosis and clinical high risk: evidence from [<sup>18</sup>F]SynVesT-1 PET.

Translational psychiatry·2026
Same author

Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis.

Molecular psychiatry·2026
Same author

Correction: "Ask" or "Inquire": operationalizing speech formality in psychosis and its risk states using etymology.

NPP - digital psychiatry and neuroscience·2025
Same author

Glutamate, NAA, and energy metabolism in clinical high risk and first episode psychosis.

Scientific reports·2025

Area of Science:

  • Neuroscience
  • Geriatric Psychiatry
  • Clinical Psychology

Background:

  • Depression frequently co-occurs with Alzheimer's disease and other dementias.
  • This comorbidity negatively impacts patient quality of life, functional abilities, and cognitive trajectory.
  • It also increases caregiver burden and is linked to higher mortality rates.

Purpose of the Study:

  • To review the current understanding of depression in Alzheimer's disease.
  • To highlight the underdiagnosis and undertreatment of this condition.
  • To discuss effective pharmacological interventions for depression in dementia.

Main Methods:

  • Review of recent randomized controlled trials.
  • Analysis of treatment efficacy for depression in Alzheimer's disease.
  • Consideration of potential side effects of psychoactive compounds.

Main Results:

  • Sertraline and moclobemide have demonstrated efficacy in treating depression in Alzheimer's disease patients.
  • Many patients with depression in this population remain untreated or receive inadequate treatment.
  • Other medications may offer benefits but require careful monitoring for adverse effects.

Conclusions:

  • Effective treatment options for depression in Alzheimer's disease are available.
  • Improved diagnostic practices and appropriate treatment are crucial for managing comorbid depression.
  • Careful consideration of drug interactions and side effects is essential when prescribing.

Related Experiment Videos